Esperion to Participate in Jefferies Healthcare Conference
May 24, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 12, 2023 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under...
Esperion Reports First Quarter 2023 Financial Results
May 09, 2023 07:00 ET
|
Esperion Therapeutics, Inc.
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position...
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 04, 2023 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”)...
Esperion to Participate in JMP Securities Life Sciences Conference
May 01, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP...
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
April 27, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America...
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
April 25, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on...
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
April 19, 2023 08:42 ET
|
Esperion Therapeutics, Inc.
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales...
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
April 03, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd...
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 22, 2023 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an...